Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 49, 2014 - Issue 12
Submit an article Journal homepage
307
Views
2
CrossRef citations to date
0
Altmetric
Pancreas

Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort

Constantin Maier-StockerDepartment of Internal Medicine I, University Hospital, Tübingen, Germany
,
Michael BitzerDepartment of Internal Medicine I, University Hospital, Tübingen, Germany
,
Nisar P. MalekDepartment of Internal Medicine I, University Hospital, Tübingen, Germany
&
Ruben R. PlentzDepartment of Internal Medicine I, University Hospital, Tübingen, GermanyCorrespondence[email protected]
Pages 1480-1485 | Received 29 Jul 2014, Accepted 12 Oct 2014, Published online: 12 Nov 2014

References

  • Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. Cancer J Clin 2010;60:277–300.
  • Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607–20.
  • Hidalgo M. Pancreatic cancer: an overview. N Engl J Med 2010;362:1605–17.
  • Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163–72.
  • Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347–53.
  • Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–6.
  • Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–25.
  • Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–703.
  • Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 2013;24:1972–9.
  • Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, et al. S3-guideline exocrine pancreatic cancer. Z Gastroenterol 2013;51:1395–440.
  • Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008;99:6–13.
  • Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011;47:1676–81.
  • Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, et al. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012;18:1357–64.
  • Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014;20:2224–36.
  • Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-Line oxaliplatin, folinic acid, and fluorouracil versus acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-OO3 Trial. J Clin Oncol 2014; Epub ahead of print.
  • Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomized phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009;101:1658–63.
  • Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:2046–52.
  • Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, et al. S-1monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol 2010;40:567–72.
  • Ky V, Hav M, Berrevoet F, Troisi RI, Ferdinande L, Monsaert E, et al. Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma. Pancreas 2013;42:1138–42.
  • Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, et al. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol 2014;73:839–45.
  • Zaanan A, Trouilloud I, Markoutsaki T, Gauthier M, Dupont-Gossart AC, Lecomte T, et al. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer 2014;14:441.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.